



# CLINICAL TRIALS CHOOSE FRANCE

# 5 good reasons to choose France to conduct your clinical studies

1.

France is a leading country in the field of health and offers know-how recognized world-wide. It's a large market, in the heart of Europe, the second most populous country in the European Union.

2.

There are numerous medical and scientific resources for clinical trials with dedicated infrastructures and specialized expertise (national clusters and networks, oncology centers, clinical investigation centers, clinical research centers).

3.

Renowned opinion leaders and professionals in clinical research, highly qualified for conducting clinical studies.

4.

Extensive experience in designing and running complex and innovative projects and clinical data management.

5.

Benefit from new, faster and more efficient business processes for contractualizing and submitting applications to the authorities.

## Key figures on the health sector



**90 billion euros**  
in turnover



**3,100 companies**  
and **201,000 direct jobs**



**#1 in Europe** in number of patents  
filed in the medical sector



**3<sup>rd</sup> largest export sector**

## Key figures on clinical trials



**1,374** eclinical trials started in France  
in 2017 (536 to industrial promotion,  
839 to academic promotion)  
(Source: clinicaltrials.gov)



France participates in **12%** of the clinical  
trials for drug industry and in **19%** of clinical  
trials for oncology  
(Source: 2018 LEEM study)



**90 %** of drug and therapy trials  
are authorized within a time period  
shorter than the regulatory timeline  
(Source: 2018 annual review National Agency  
for drug safety regulation)



Since October 15, 2018, the national  
regulatory Authority applies **2 Fast Track**  
procedures for clinical trials dedicated to  
drugs and advanced therapies  
(Source: 2018 annual review, Drug regulation  
national authority)

# They have already made France their choice

France is an ideal place to conduct research and experimentation in the health sector. **10% of international clinical research studies are carried out in France.**

## #1 IN EUROPE IN NUMBER OF CLINICAL STUDIES

France, an **ideal environment** for conducting clinical trials:

- \_ Scientific and medical skills recognized internationally, including with respect to investigators.
- \_ The quality of research and care infrastructures provide all the tools and ecosystem institutions may need to conduct their work.
- \_ The speed of enrollment in studies.

The **3 major areas** in which clinical research work in France focuses, for drugs:

- \_ Oncology and oncohaematology (45% of trials worldwide)
- \_ Advanced/innovative therapy drugs
- \_ Rare diseases

## Distribution of clinical trials of medical devices by main therapeutic area

CARDIOLOGY

**23.7%**

DERMATOLOGY

**10.5%**

ANAESTHESIOLOGY/REANIMATION

**8.4%**

ORTHOPEDIA

**7.4%**

OPHTHALMOLOGY

**6.3%**

DIAGNOSTIC IMAGING

**5.3%**



## PHARM-OLAM

**Frédérique FAUDET**

Clinical development headquarter, Pharm Olam

"According to Frederique Fauduet, Pharm-Olam's Director of Clinical Development: "In France we have always had a strong scientific and academic history and even today there are currently over 4000 open clinical studies around the country. You can find key opinion leaders in all the major fields working at the leading French medical institutes. Several improvements in the regulatory process coupled with the EU Horizon 2020 initiative and the R&D Tax Credit scheme have helped France continue to be one of the leaders of clinical research within the EU."

---



## MSD FRANCE

**Cyril SCHIEVER**

Chairman of MSD France

"Thanks to the recognized quality of its research ecosystem and healthcare system, France is a paramount country for a laboratory such as MSD. For the past year, the new political impetus in favor of innovation has strengthened our R&D and digital investment plans. The signals sent out by the Strategic Council of Health Industries, which are expected improve conditions for access to the market for therapeutic innovations and boost the attractiveness of clinical research, give us hope for an even more innovation-oriented environment, which will encourage us to increase our investments in France."

---



## MEDTRONIC

**Cécile FOURET**

Medtronic France Country Clinical Manager

"France has become a benchmark partner for Medical Device International Research. In 3 years, the timeframe required to conduct clinical studies has been significantly reduced in this country."

# Clinical trials: opportunities for researchers and healthcare industry players

## AN ATTRACTIVE LOCATION FOR CONDUCTING RESEARCH

France offers researchers, academic research teams and healthcare industries a dynamic ecosystem to carry out collaborative work with cutting-edge research centers, hospitals and companies.

France is the only European country to have made the list of the world's Top 10 health research centers, with two excellence research centers: the French National Institute of Health and Medical Research (INSERM) and the Paris Public Hospitals (AP-HP).



**30** innovative university hospitals



**28M** admissions per year



**1** national agreement on clinical trials in hospitals for all industrial research (time saving for industrials and investigators centers)



**1** new information and awareness-raising website for clinical research aimed at the general public (<https://notre-recherche-clinique.fr>)



More than **50** centers of expertise dedicated to clinical investigation throughout France



**15** national thematic investigative networks (F-CRIN)



**16** INCa-labelled centres for early-phase cancer researchh (CLIP<sup>2</sup>)



**1** tightly-meshed network of 3,000 public and private healthcare institutions

## MANY GRANTS TO SUPPORT RESEARCH

There exist numerous support mechanisms for researchers and research centres: grants, funding and tax support in particular.

The R&D tax incentive program is the most attractive of any OECD country, thanks in particular to an advantageous research tax credit (CIR). The tax credit amounts to 30% of R&D expenditure up to €100 million and 5% beyond that threshold.

Note:

- Expenditures subcontracted to public bodies are taken into account at a rate of 200%,
- Remuneration for young doctoral students is taken into account at a rate of 400%,
- Depreciation of research material is taken into account at a rate of 175%.

## More than €7 billion in research expenditure

Healthcare companies invest more than €7 billion per year in R&D in France, and France is the European leader in terms of number of patents filed in the health sector.

## CONTACTS

### FOR RESEARCH IN PUBLIC HOSPITALS:

CNCR (National Committee for Research Coordination)  
52, rue Maurice-Ripoche, 75014 Paris, FRANCE  
[www.cncr.fr/contact/](http://www.cncr.fr/contact/)

### FOR CANCER RESEARCH:

UNICANCER  
101, rue de Tolbiac, 75654 Paris Cedex 13, FRANCE  
Tel.: +33 1 85 34 36 25  
Dr Claire Labreuveux, MD - [c-labreuveux@unicancer.fr](mailto:c-labreuveux@unicancer.fr)

### FOR A FRENCH PARTNER IN SPECIFIC MEDICAL AREAS:

F-CRIN (French Clinical Research Infrastructure Network)  
Pavillon Leriche - 2<sup>e</sup> étage - CHU de Toulouse  
Place du Dr-Baylac - TSA 400031, 31059 Toulouse Cedex 09, FRANCE  
Tel.: + 33 (0)5 34 55 75 93 - [contact@fcrin.org](mailto:contact@fcrin.org) - [www.fcrin.org](http://www.fcrin.org)



**FRENCH HEALTHCARE is an innovative public private initiative aimed at bringing together the key players in the French healthcare ecosystem (companies, researchers, healthcare professionals and key players), to help them to promote their activity, expertise and technologies internationally.**

Produced with the support of French Healthcare Association members



Produced with the support of

